|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 51/00 | |
| A61K 39/42 | |||
| A61K 39/40 | |||
| A61K 47/18 | |||
| A61K 47/42 |
| (11) | Number of the document | 1729821 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05731866.9 |
| Date of filing the European patent application | 2005-03-03 | |
| (97) | Date of publication of the European application | 2006-12-13 |
| (45) | Date of publication and mention of the grant of the patent | 2013-07-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2005/007524 |
| Date | 2005-03-03 |
| (87) | Number | WO 2005/084410 |
| Date | 2005-09-15 |
| (30) | Number | Date | Country code |
| 550015 P | 2004-03-03 | US |
| (72) |
DAKE, Michael D., US
WAUGH, Jacob M., US
|
| (73) |
ReVance Therapeutics, Inc.,
2400 Bayshore Parkway, Mountain View CA 94043,
US
|
| (54) | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS |
| COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS |